Financial Data and Key Metrics Changes - For Q3 2025, cash NOI was $42.8 million, a 4.9% increase from $40.8 million in Q3 2024, driven by acquisition activity and same-store cash NOI growth of 1.2% [15] - AFFO per share decreased by 0.8% compared to Q3 2024, primarily due to increased interest expense, but increased by 4.2% compared to Q2 2025 [16] - The percentage of reporting obligors increased by 2.4% to 75.8%, with an EBITDA rent coverage ratio of 6.19 times, up from 5.31 times in Q2 2025 [16][17] Business Line Data and Key Metrics Changes - Significant acquisitions included the $16.3 million Southlake portfolio and the $70.5 million Reunion Novus portfolio, totaling approximately $87 million [4][6] - The company successfully renewed 90% of its 2025 lease expirations, with three lease renewals accounting for approximately 58,000 sq ft [11] Market Data and Key Metrics Changes - The company is focused on acquiring healthcare assets in markets with strong and growing demographics, particularly in Texas and Arizona [5][6] - The anticipated cap rate is expected to tighten due to looser central bank monetary policy [10] Company Strategy and Development Direction - The company aims to grow strategically and accretively, focusing on high-performing triple net lease healthcare assets [20] - Expansion opportunities are being pursued to meet the ongoing demand for high-quality healthcare services [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding tenant credit and rent collection, highlighting strong coverage ratios [30] - The company remains focused on maintaining a robust balance sheet and low leverage while exploring acquisition opportunities [18][19] Other Important Information - The board authorized a share repurchase program of up to $75 million over three years, with no shares purchased during the quarter [18] - An at-the-market equity offering sales agreement was established, but no shares have been issued under this program to date [19] Q&A Session Summary Question: Was the CHS termination payment in Q3 or Q4, and how much was it? - The CHS termination payment is expected in Q4, approximately a couple hundred thousand dollars [23] Question: What other factors might impact the income statement in Q4? - Continued decreased carry costs for Stoughton and lower G&A expenses are expected to positively impact the income statement [24][25] Question: How much additional capacity exists for deals without needing to issue equity? - The company estimates around $200 to $220 million capacity to stay within targeted leverage ranges [27] Question: How is the tenant credit watch list evolving? - The watch list is stable, with cautious optimism regarding tenant performance and lease renewals [29] Question: How does the company evaluate development or expansion projects? - Most opportunities arise from tenant requests, with the company monitoring tenant financials and operational performance [48] Question: How does the company view the risk of potential changes in ACA subsidies? - The company believes it is insulated from risks associated with ACA subsidy changes due to its focus on outpatient and lower-cost patient settings [50] Question: Is the company closer to utilizing the ATM program or the buyback program? - The company prefers not to issue equity at current levels due to dilution concerns and is focused on thoughtful capital deployment [51]

Financial Data and Key Metrics Changes - The company reported cash NOI of $41.9 million for Q2 2025, a 1.7% increase from Q2 2024, primarily driven by acquisitions [12] - AFFO was $0.54 per diluted share for Q2 2025, reflecting a 1.7% increase from Q2 2024, despite a 2.7% decrease year-over-year due to higher interest expenses [13][15] - The liquidity position at the end of the quarter was $568.8 million, with a net debt to EBITDAre ratio of 3.6 times [17] Business Line Data and Key Metrics Changes - The average EBITDARM coverage ratio improved to 5.31 times, up from 4.64 times in the previous year, indicating stronger tenant performance [16] - The company maintained a strong tenant base, with 40% associated with investment-grade rated tenants, up from 36.4% year-over-year [16] Market Data and Key Metrics Changes - The company closed on a two-property medical outpatient building portfolio for approximately $16.2 million, enhancing its operational synergies [20] - Year-to-date acquisitions totaled approximately $75 million, with over $70 million of properties under exclusive LOI [21] Company Strategy and Development Direction - The company focuses on necessity-based healthcare solutions, aiming to capitalize on the aging population and limited competition in its markets [5][19] - A strategic decision was made to demolish the Stoughton asset to halt expense leakage and maximize future land value [10][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow despite macroeconomic uncertainties, emphasizing a prudent capital allocation strategy [4][11] - The company aims to maintain a healthy dividend while pursuing growth through acquisitions and share repurchases [17] Other Important Information - The board approved a three-year share repurchase program for up to $75 million, with a cap of $25 million per year [15] - The company is currently under exclusive LOI for additional acquisitions, indicating a robust pipeline for future growth [21] Q&A Session Summary Question: What types of assets are included in the $70 million LOIs? - Management confirmed that the properties under LOI are consistent with their current portfolio and have long lease durations [25][26] Question: What is the current status of the Stoughton facility? - Management indicated that the demolition process is underway and will significantly reduce carrying costs [39][57] Question: How does the company evaluate share repurchases versus acquisitions? - Management stated that share repurchases are viewed as a tool, and decisions are based on the perceived disconnect between share price and intrinsic value [30][41] Question: What are the expectations for lease expirations in the near term? - Management is optimistic about renewing nearly all leases expiring in 2025 and 2026, with only minor exposures expected [42][46]